Genmab Licenses Synaffix’s Antibody-Drug Conjugate Technologies

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 1 (Table of Contents)

Published: 10 Jan-2022

DOI: 10.3833/pdr.v2022.i1.2654     ISSN: 1756-7874

Section: Licensing



Continuing its interest in antibody-drug conjugate (ADC) therapies, Genmab has agreed to pay US$4...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details